Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Zidovudine update: 1990.

G D Morse1, J L Lechner, J A Santora

  • 1State University of New York, Buffalo.

DICP : the Annals of Pharmacotherapy
|July 1, 1990
PubMed
Summary

Zidovudine (ZDV) offers effective human immunodeficiency virus (HIV) treatment. Lower doses (500 mg/d) show equivalence, benefiting asymptomatic patients with CD4+ counts below 500/mm3.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical pharmacology quality assurance for HIV and related infectious diseases research.

Clinical pharmacology and therapeutics·2013
Same author

Pharmacokinetics of the nonnucleoside reverse transcriptase inhibitor efavirenz among HIV-infected Ugandans.

HIV medicine·2011
Same author

Update on the pharmacokinetic aspects of antiretroviral agents: implications in therapeutic drug monitoring.

Current pharmaceutical design·2006
Same author

Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors.

Clinical pharmacokinetics·2001
Same author

Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings.

Pediatrics·2001
Same author

Glucose disorders associated with HIV and its drug therapy.

The Annals of pharmacotherapy·2001

Area of Science:

  • Pharmacology
  • Virology
  • Infectious Diseases

Background:

  • Zidovudine (ZDV) is the sole U.S.-approved antiviral for HIV infection.
  • It serves as the benchmark for new antiviral drug comparisons.
  • Previously, ZDV was prescribed at 1500 mg/d for advanced HIV/AIDS-related complex (ARC).

Purpose of the Study:

  • To evaluate the efficacy of a reduced ZDV dosage (500 mg/d).
  • To assess ZDV's benefit in asymptomatic HIV patients with specific CD4+ counts.
  • To review ZDV's toxicity profile, pharmacokinetics, and drug interactions.

Main Methods:

  • Review of clinical studies on ZDV efficacy and safety.
  • Analysis of pharmacokinetic data including bioavailability, half-life, clearance, and volume of distribution.
  • Examination of drug interaction profiles, particularly with agents undergoing hepatic glucuronidation.

Main Results:

  • A lower daily dose of 500 mg ZDV appears equivalent to the previous 1500 mg/d dose.
  • ZDV therapy demonstrates benefits for asymptomatic HIV patients with CD4+ counts < 500/mm3.
  • ZDV exhibits variable pharmacokinetics and potential drug interactions, primarily affecting its clearance.

Conclusions:

  • Reduced ZDV dosage is effective and may offer a better safety profile.
  • ZDV is beneficial in earlier stages of HIV infection.
  • Ongoing research explores ZDV in diverse patient populations and combination therapies.

Related Experiment Videos